BeiGene’s Sonrotoclax was granted FDA orphan designation as a treatment of multiple myeloma, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BGNE:
- BeiGene, Ensem Therapeutics partner on CDK2 inhibitor
- BeiGene receives European Commission approval for BRUKINSA
- BeiGene price target raised to $200 from $180.18 at BofA
- BeiGene reports Q3 EPS $2.01, consensus ($3.09)
- BGNE Upcoming Earnings Report: What to Expect?
Questions or Comments about the article? Write to editor@tipranks.com